KEYTRUDA Padcev MIBC Survival: New Era in Treat...

By HEOR Staff Writer

March 2, 2026

KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Revised MenACWY Vaccination Strategy for Adolescents in Germany